1990-2023: Value through Innovation
The Boehringer Ingelheim history from 1990 to 2023, with milestones
Search
Tackling NCDs through innovation AND collaboration
Non-communicable diseases are a significant medical, humanitarian and socio-economic issue. Rapid innovation and holistic approaches help us tackle them
U.S. FDA approves first treatment for generalized pustular psoriasis flares in adults
Boehringer Ingelheim announces the U.S. FDA has approved the first treatment for generalized pustular psoriasis (GPP) flares in adults
GPP Interview with Professor Barker
An interview with Prof. Barker about generalized pustular psoriasis, its burden on patients and how patient outcomes can be improved
collaboration-Yale
Yale-Boehringer Ingelheim Biomedical Data Science Fellowship Program Seeks to Attract Top Researchers from Around the World
Strategic-collaboration-with-EnaraBio
Boehringer Ingelheim and Enara Bio enter strategic collaboration and licensing agreement to discover novel shared antigens for cancer immunotherapies.
2019 performance
Global Support Program addresses COVID-19 crisis with relief fund initiatives and volunteering support, donations, and concrete research activities.
Boehringer-Ingelheim's-half-year-figures-2021
Press release on Boehringer Ingelheim's half-year figures 2021. Business development from January to June 2021.
AI&Data Science Fellowship Tuebingen
AI&Data Science Fellowship Tuebingen
Better Access to Healthcare for Indigenous Peoples
Indigenous Peoples often experience poor access to health care. Our initiatives from Canada and New Zealand aim to overcome the gap.
Growing with us
We recognize the benefits of learning and have created an environment where life-long learning and personal growth are encouraged for all employees.
Boehringer Ingelheim good 2021 business performance
2021 was a good year for patients, for animal owners and for Boehringer Ingelheim.
Performance Indicators
Performance indicators concerning Environment Health and Safety (EHS) are summarized here.
Geographic Atrophy treatment to move to Phase II
Geographic Atrophy treatment BI 771716 to move to Phase II, following positive Phase I results
empa-reg-outcome-recurrent-events
EMPA-REG OUTCOME® analysis: Empagliflozin reduced risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and CV disease